文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

口服莫西沙星与静脉厄他培南联合口服左氧氟沙星治疗非复杂性急性阑尾炎的APPAC II随机临床试验

Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

APPAC II多中心开放标签非劣效随机试验纳入599例CT确诊的非复杂性急性阑尾炎成人患者,比较口服莫西沙星7天与静脉厄他培南2天序贯口服左氧氟沙星和甲硝唑5天的疗效。

要点

  • 两组1年治疗成功率均>65%,但口服莫西沙星未达到非劣效于静脉序贯口服方案。
  • 口服组成功率70.2%,静脉序贯口服组73.8%,差值-3.6%(单侧95%CI -9.7%至∞)。
  • 非劣效界值设为6%,置信下限-9.7%超出界值,非劣效未成立。

核心结论

  • 口服莫西沙星7天与静脉厄他培南2天序贯口服左氧氟沙星和甲硝唑5天相比,两组治疗成功率均超过65%,但未能证明口服方案非劣效。

研究设计与样本

  • 共纳入599例18至60岁CT确诊的非复杂性急性阑尾炎患者,随机分为口服单药组(n=295)和静脉序贯口服组(n=288)。
  • 主要终点为治疗成功,定义为出院未手术且1年随访内无复发性阑尾炎,非劣效界值为6%。

主要发现

  • 599例随机患者平均(SD)年龄36(12)岁,女性263例(44%),581例(99.7%)完成1年随访。
  • 口服组1年治疗成功率为70.2%(单侧95%CI 65.8%至∞),静脉序贯口服组为73.8%(单侧95%CI 69.5%至∞)。

关键数值与推荐

  • 非劣效界值为6%,以1年治疗成功率差值评估。
  • 口服组方案为口服莫西沙星400 mg/d持续7天。
  • 静脉序贯口服组方案为静脉厄他培南1 g/d持续2天,继以口服左氧氟沙星500 mg/d和甲硝唑500 mg每日3次持续5天。

临床怎么用

  • 对于CT确诊的非复杂性急性阑尾炎成人,口服莫西沙星单药方案未证明非劣效于静脉序贯口服方案,临床选择抗生素方案时需考虑此结果。

局限性

  • 开放标签设计可能引入偏倚。
  • 非劣效界值设定为6%,结果置信区间较宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Antibiotics are an effective and safe alternative to appendectomy for managing uncomplicated acute appendicitis, but the optimal antibiotic regimen is not known. OBJECTIVE: To compare oral antibiotics with combined intravenous followed by oral antibiotics in the management of computed tomography-confirmed uncomplicated acute appendicitis. DESIGN, SETTING, AND PARTICIPANTS: The Appendicitis Acuta (APPAC) II multicenter, open-label, noninferiority randomized clinical trial was conducted from April 2017 until November 2018 in 9 Finnish hospitals. A total of 599 patients aged 18 to 60 years with computed tomography-confirmed uncomplicated acute appendicitis were enrolled in the trial. The last date of follow-up was November 29, 2019. INTERVENTIONS: Patients randomized to receive oral monotherapy (n = 295) received oral moxifloxacin (400 mg/d) for 7 days. Patients randomized to receive intravenous antibiotics followed by oral antibiotics (n = 288) received intravenous ertapenem (1 g/d) for 2 days followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d) for 5 days. MAIN OUTCOMES AND MEASURES: The primary end point was treatment success (≥65%) for both groups, defined as discharge from hospital without surgery and no recurrent appendicitis during 1-year follow-up, and to determine whether oral antibiotics alone were noninferior to intravenous and oral antibiotics, with a margin of 6% for difference. RESULTS: Among 599 patients who were randomized (mean [SD] age, 36 [12] years; 263 [44%] women), 581 (99.7%) were available for the 1-year follow-up. The treatment success rate at 1 year was 70.2% (1-sided 95% CI, 65.8% to ∞) for patients treated with oral antibiotics and 73.8% (1-sided 95% CI, 69.5% to ∞) for patients treated with intravenous followed by oral antibiotics. The difference was -3.6% ([1-sided 95% CI, -9.7% to ∞]; P = .26 for noninferiority), with the confidence limit exceeding the noninferiority margin. CONCLUSION AND RELEVANCE: Among adults with uncomplicated acute appendicitis, treatment with 7 days of oral moxifloxacin compared with 2 days of intravenous ertapenem followed by 5 days of levofloxacin and metronidazole resulted in treatment success rates greater than 65% in both groups, but failed to demonstrate noninferiority for treatment success of oral antibiotics compared with intravenous followed by oral antibiotics. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03236961; EudraCT Identifier: 2015-003633-10.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Sippola S, Haijanen J, Grönroos J, et al. Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis: The APPAC II Randomized Clinical Trial. JAMA. 2021. PMID: 33427870. doi:10.1001/jama.2020.23525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。